Robert, Theresa, and Tomas connecting with partners and peers at ECIO to discuss our work advancing IP-001, aimed at transforming tumor ablation from a local procedure into a systemic cancer therapy.

These discussions reflect an ongoing exchange of ideas and insights within interventional therapeutics, supporting the continued advancement of IP-001 through clinical trials.

Our focus is clear: bring this novel therapy to patients in need as quickly as possible.

At Booth #20, Immunophotonics is featured for its work in Interventional Immuno-Oncology®, a novel intratumoral approach designed to reduce tumor recurrence following standard ablation procedures.